Clinical Review Identifies Key Biological and Environmental Drivers Behind Higher Immunotherapy Success Rates in Asian Gastric Cancer Patients

A new clinical review explains why Asian gastric cancer patients see higher survival rates in immunotherapy trials due to genetics, screening, and tumor biology.

By: AXL Media

Published: Mar 27, 2026, 10:16 AM EDT

Source: Information for this report was sourced from the Chinese Academy of Sciences.

The Global Survival Gap in Advanced Gastric Cancer

Advanced gastric cancer remains a high-mortality disease, with a global 5-year survival rate languishing below 10%. While the introduction of immunotherapy combined with chemotherapy has raised the ceiling for treatment, a recurring statistical trend has emerged across major global trials: Asian patients often experience significantly stronger antitumor responses. This review, led by researchers from the Chinese PLA General Hospital and MSD China, analyzes data from pivotal trials—including CheckMate-649 and KEYNOTE-859—to determine why geography and ethnicity appear to correlate so strongly with patient survival and treatment efficacy.

Statistical Evidence from Pivotal Immunotherapy Trials

The review synthesizes outcomes from several landmark studies that established the current standard of care. In many of these datasets, the survival benefit for Asian cohorts was markedly higher. For instance, in trials assessing PD-1 inhibitors as first-line treatment, the hazard ratios for death were consistently more favorable in Asian subgroups than in Western populations. The researchers argue that these results are not anomalies but are rooted in a "layered interaction" between tumor genetics, host immunity, and even environmental exposures like microbiome composition and prior infections.

Molecular Subtypes and Mutation Frequencies

A primary driver of the disparity lies at the molecular level. The review highlights that immunotherapy-responsive subtypes—specifically Microsatellite Instability (MSI) and Epstein-Barr Virus (EBV)-positive tumors—tend to be more frequent in certain Asian cohorts. Conversely, Chromosomal Instability (CIN) and genomically stable tumors, which are often less responsive to immune checkpoint inhibitors (ICIs), are more common in Western populations. Furthermore, the study identifies distinct population-level differences in somatic mutation frequencies within genes such as: